J. J. Weening, D. 'agati, V. D. Schwartz, M. M. Seshan, S. V. Alpers et al., The classification of glomerulonephritis in systemic lupus erythematosus revisited, J Am Soc Nephrol, vol.15, pp.241-50, 2004.

B. Terrier, M. I. Lacraz, A. Belenotti, P. Bonnet, F. Chiche et al., Non HCVrelated infectious cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey and systematic review of the literature, J Autoimmun, vol.65, pp.74-81, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02032951

F. Fakhouri, V. Fré-meaux-bacchi, L. H. Noë-l, H. T. Cook, and M. C. Pickering, C3 glomerulopathy: a new classification, Nat Rev Nephrol, vol.6, pp.494-503, 2010.

A. Servais, V. Fremeaux-bacchi, M. Lequintrec, R. Salomon, J. Blouin et al., Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome, J Med Genet, vol.44, pp.193-202, 2007.

S. H. Nasr, A. M. Valeri, G. B. Appel, J. Sherwinter, M. B. Stokes et al., Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients, Clin J Am Soc Nephrol, vol.4, pp.22-32, 2009.

A. Servais, . Noë-l-lh, L. T. Roumenina, L. Quintrec, M. Ngo et al., Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies, Kidney Int, vol.82, pp.454-64, 2012.

M. C. Pickering, H. T. Cook, J. Warren, A. E. Bygrave, J. Moss et al., Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H, Nat Genet, vol.31, pp.424-432, 2002.

G. A. Hegasy, T. Manuelian, K. Hogasen, J. H. Jansen, and P. F. Zipfel, The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion, Am J Pathol, vol.161, pp.2027-2061, 2002.

F. Fakhouri, E. G. De-jorge, F. Brune, P. Azam, H. T. Cook et al., Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice, Kidney Int, vol.78, pp.279-86, 2010.

K. L. Rose, D. Paixao-cavalcante, J. Fish, A. P. Manderson, T. H. Malik et al., Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice, J Clin Invest, vol.118, pp.608-626, 2008.

C. Blanc, S. K. Togarsimalemath, S. Chauvet, L. Quintrec, M. Moulin et al., Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases, J Immunol, vol.194, pp.5129-5167, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01843975

Q. Chen, D. Muller, B. Rudolph, A. Hartmann, E. Kuwertz-brö-king et al., Combined C3b and factor B autoantibodies and MPGN type II, N Engl J Med, vol.365, pp.2340-2342, 2011.

J. Hou, G. S. Markowitz, A. S. Bomback, G. B. Appel, L. C. Herlitz et al., Toward a working definition of C3 glomerulopathy by immunofluorescence, Kidney Int, vol.85, pp.450-456, 2014.

M. C. Pickering, D. 'agati, V. D. Nester, C. M. Smith, R. J. Haas et al., C3 glomerulopathy: consensus report, vol.84, pp.1079-89, 2013.

M. A. Little, P. Dupont, E. Campbell, A. Dorman, and J. J. Walshe, Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk, Kidney Int, vol.69, pp.504-515, 2006.

L. Zand, A. Kattah, F. C. Fervenza, R. J. Smith, S. H. Nasr et al., C3 glomerulonephritis associated with monoclonal gammopathy: a case series, Am J Kidney Dis, vol.62, pp.506-520, 2013.

S. Meri, V. Koistinen, A. Miettinen, T. Tornroth, and I. J. Seppala, Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis, J Exp Med, vol.175, pp.939-50, 1992.

T. S. Jokiranta, A. Solomon, M. K. Pangburn, P. F. Zipfel, and S. Meri, Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H, J Immunol, vol.163, pp.4590-4596, 1999.

C. Rabasco, T. Cavero, E. Roman, J. Rojas-rivera, T. Olea et al., Effectiveness of mycophenolate mofetil in C3 glomerulonephritis, Kidney Int, vol.88, pp.1153-60, 2015.

E. C. Lorenz, S. Sethi, N. Leung, A. Dispenzieri, F. C. Fervenza et al., Recurrent membranoproliferative glomerulonephritis after kidney transplantation, Kidney Int, vol.77, pp.721-729, 2010.

R. J. Smith, J. Alexander, P. N. Barlow, M. Botto, T. L. Cassavant et al., New approaches to the treatment of dense deposit disease, J Am Soc Nephrol, vol.18, pp.2447-56, 2007.

K. Haffner, S. Michelfelder, and M. Pohl, Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression, Pediatr Nephrol, vol.30, pp.1951-1960, 2015.

C. Rousset-rouviè-re, M. Cailliez, F. Garaix, D. Bruno, D. Laurent et al., Rituximab fails where eculizumab restores renal function in C3nef-related DDD, Pediatr Nephrol, vol.29, pp.1107-1118, 2014.

E. Daina, M. Noris, and G. Remuzzi, Eculizumab in a patient with dense-deposit disease, N Engl J Med, vol.366, pp.1161-1164, 2012.

M. C. Pickering, J. Warren, K. L. Rose, F. Carlucci, Y. Wang et al., Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice, Proc Natl Acad Sci, vol.103, pp.9649-54, 2006.

L. Quintrec, M. Lionet, A. Kandel, C. Bourdon, F. Gnemmi et al., Eculizumab for treatment of rapidly progressive C3 glomerulopathy, Am J Kidney Dis, vol.65, pp.484-493, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01843971